Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yet-Sen University, Guangzhou, China.
Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yet-Sen University, Guangzhou, China.
Adv Nutr. 2017 Sep 15;8(5):684-693. doi: 10.3945/an.116.014852. Print 2017 Sep.
Numerous clinical trials have examined the role of anthocyanins on cardiometabolic health, but their effects have not been quantitatively synthesized and systematically evaluated. The aim of our study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of anthocyanins on glycemic regulation and lipid profiles in both healthy populations and those with cardiometabolic diseases. The MEDLINE, EMBASE, Cochrane database, OVID EBM Reviews, and clinicaltrials.gov databases were searched until February 2017. RCTs with a duration of ≥2 wk that evaluated the effects of anthocyanins on glycemic control, insulin sensitivity, and lipids as either primary or secondary outcomes were included. The Cochrane Risk of Bias tool was used to assess the study quality. Standardized mean differences (SMDs) were determined by random-effects models. Meta-regression, sensitivity, and subgroup analyses were performed to explore the influence of covariates on the overall effects. Thirty-two RCTs (1491 participants) were eligible for meta-analysis. Anthocyanins significantly reduced fasting glucose (SMD: -0.31; 95% CI: -0.59, -0.04; = 80.7%), 2-h postprandial glucose (SMD: -0.82; 95% CI: -1.49, -0.15; = 77.7), glycated hemoglobin (SMD: -0.65; 95% CI: -1.00, -0.29; = 72.7%), total cholesterol (SMD: -0.33; 95% CI: -0.62, -0.03; = 86.9%), and LDL (SMD: -0.35; 95% CI: -0.66, -0.05; = 85.2%). Sensitivity analyses showed that the overall effects remained similar by excluding the trials with a high or unclear risk of bias. The significant improvements in glycemic control and lipids support the benefits of anthocyanins in the prevention and management of cardiometabolic disease. Further well-designed RCTs are needed to evaluate the long-term effects of anthocyanins on metabolic profiles and to explore the optimal formula and dosage. The protocol for this review was registered at https://www.crd.york.ac.uk/PROSPERO/#index.php as CRD42016033210.
已有大量临床试验研究了花色苷对心血管代谢健康的作用,但尚未对其进行定量综合评估。本研究旨在对花色苷对健康人群和心血管代谢疾病患者血糖调节和血脂谱影响的随机对照试验(RCT)进行系统综述和荟萃分析。检索了 MEDLINE、EMBASE、Cochrane 数据库、OVID EBM Reviews 和 clinicaltrials.gov 数据库,截至 2017 年 2 月。纳入了持续时间≥2 周、评估花色苷对血糖控制、胰岛素敏感性和血脂作为主要或次要结局影响的 RCT。使用 Cochrane 偏倚风险工具评估研究质量。采用随机效应模型确定标准化均数差(SMD)。进行荟萃回归、敏感性和亚组分析,以探讨协变量对总体效应的影响。32 项 RCT(1491 名参与者)符合荟萃分析条件。花色苷可显著降低空腹血糖(SMD:-0.31;95%CI:-0.59,-0.04; = 80.7%)、餐后 2 小时血糖(SMD:-0.82;95%CI:-1.49,-0.15; = 77.7%)、糖化血红蛋白(SMD:-0.65;95%CI:-1.00,-0.29; = 72.7%)、总胆固醇(SMD:-0.33;95%CI:-0.62,-0.03; = 86.9%)和 LDL(SMD:-0.35;95%CI:-0.66,-0.05; = 85.2%)。敏感性分析显示,排除高风险或不确定偏倚的试验后,总体效应仍相似。血糖控制和血脂的显著改善支持花色苷在预防和治疗心血管代谢疾病中的益处。需要进一步设计良好的 RCT 来评估花色苷对代谢谱的长期影响,并探索最佳配方和剂量。本研究方案已在 https://www.crd.york.ac.uk/PROSPERO/#index.php 注册,注册号为 CRD42016033210。